Leukemia :: GX15-070 Active in Refractory CLL

According to results recently presented at the 47th annual meeting of the American Society of Hematology (ASH), the agent GX15-070, which is still in clinical trials, has anticancer activity in patients with chronic lymphocytic leukemia (CLL) who have stopped responding to standard therapies including chemotherapy, Rituxan?, and Campath?.

Researchers from the MD Anderson Cancer Center, the University of California at San Diego, the princess Margaret Hospital in Toronto, and Georgetown University recently conducted a clinical trial evaluating GX15-070 as treatment for refractory CLL. This trial included 25 patients who had stopped responding to chemotherapy and Rituxan. Forty percent of patients had also stopped responding to Campath.

Patients with CLL that has stopped responding to standard therapies may wish to speak with their physician regarding their individual risks and benefits of participating in a clinical trial further evaluating GX15-070 or other novel therapeutic options.


Leave a Comment